CTOs on the Move


 
Akebia Therapeutics, Inc. is a growing biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the development and commercialization of therapeutics for people living with kidney disease.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.akebia.com
  • 245 First Street Suite 1400
    Cambridge, MA USA 02142
  • Phone: 617.871.2098

Executives

Name Title Contact Details
Amanda Foote
VP, R&D Portfolio Strategy and External Collaborations Profile
Michael Crispin
Vice President, Technology and Digital Operations Profile

Similar Companies

Park Systems

Park Systems is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mind Medicine

MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.

Metacrine

We are a clinical-stage biopharmaceutical company focused on discovering and developing best-in-class therapies for patients with liver and gastrointestinal, or GI, diseases. Since our founding in 2014, we have invested in building a foundation of chemistry and biology expertise to drive innovative drug discovery and development. We believe these internal capabilities allow us to gain insights into disease targets and mechanisms and more quickly and purposefully design therapies with characteristics that we view as key to safety and efficacy. With this systematic approach, we have designed novel, proprietary farnesoid X receptor (FXR) clinical product candidates arising from a unique chemical scaffold with the potential to be best-in-class for non-alcoholic steatohepatitis, or NASH, and first- in-class for Inflammatory Bowel Disease, or IBD. In addition to our FXR program, we have continued to invest in drug discovery on other therapeutic targets that have effects on inflammation and/or fibrosis for which we believe we could develop proprietary small molecule therapies.

Curie Co

Curie Co is replacing chemicals with clean, sustainable proteins and enzymes.

Epigentek

Epigentek is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.